NEJM publishes encouraging study data on Genmab's daratumumab monotherapy in multiple myeloma
The New England Journal of Medicine has published the full dataset from Danish biotech company Genmab (OMX: GEN) on its Phase I/II study with daratumumab monotherapy in relapsed or refractory multiple myeloma.
The data showed a 36% response rate in the 16 mg/kg group in part 2 of the study, with responses that deepened over time, and 65% of patients in this group that responded to treatment were progression-free twelve months following the start of treatment. Patients receiving 16mg/kg had a median of four prior lines of therapy, and 64% of these patients were refractory to protease inhibitors and immunomodulatory drugs, which are the current standard of care treatments for multiple myeloma.
The 16mg/kg dose was chosen as the dose to be used in future daratumumab trials. The drug is being developed by Janssen Biotech, a unit of Johnson & Johnson (NYSE: JNJ), under an exclusive license from Genmab.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze